Blog
RSS FeedPosted by Michael Wonder on 24 Sep 2015
Keryx receives European approval for Fexeric (ferric citrate coordination complex) for the treatment of hyperphosphataemia in adults with chronic kidney disease
24 September 2015 - Keryx Biopharmaceuticals, Inc. today announced that the European Commission has approved Fexeric (ferric citrate coordination complex) for ...
Posted by Michael Wonder on 23 Sep 2015
AcelRx Pharmaceuticals reports that the European Commission has granted marketing authorization for Zalviso for treatment of acute moderate-to-severe post-operative pain in adult patients
22 September 2015 - AcelRx Pharmaceuticals, Inc. announced today that the European Commission (EC) has approved Zalviso (15 micrograms sufentanil sublingual ...
Posted by Michael Wonder on 21 Sep 2015
Non-stimulant for ADHD approved in Europe
21 September 2015 - Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant Intuniv (guanfacine hydrochloride prolonged ...
Posted by Michael Wonder on 11 Sep 2015
Updated label for Daklinza (daclatasvir) for the 12-week treatment of non-cirrhotic patients with chronic hepatitis C genotype 3 approved by the European Commission
10 September 2015 - Bristol-Myers Squibb Company announced today that the European Commission has approved an updated label for Daklinza for ...
Posted by Michael Wonder on 10 Sep 2015
Santhera receives European marketing authorisation for Raxone in Leber's hereditary optic neuropathy (LHON)
9 September 2015 - Santhera Pharmaceuticals announces the European Commission (EC) has granted marketing authorisation for Raxone as the first approved ...
Posted by Michael Wonder on 04 Sep 2015
Novartis receives EU approval for Farydak, the first in its class of anticancer agents approved for patients with multiple myeloma
4 September 2015 - Novartis announced today that the European Commission has approved Farydak (panobinostat, previously known as LBH589) capsules, in ...